

MediVac Limited

ASX Announcement Code: MDV

ABN 64 055 747 941

Friday July 22 2011

Company Announcements Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000

MediVac Limited Market Update

Healthcare solutions company MediVac Limited [ASX: MDV] makes the following points in the attached Chairman's market update presentation to the Extraordinary General Meeting in Sydney today:

Improved Result for FY 2011

• The Company expects (unaudited) results for FY 2011 to show a 20% to 25% improvement (reduction in net loss) compared to the 2010 year.

Key research & development activities have been completed :

- First new MetaMizer 240 SSS has now been completed.
- New MetaMizer 240 SSS currently undergoing rigorous testing. Results to date are exceeding expectations, including faster throughput, even higher capacity and ability to treat alternative feedstock.
- New Sunnywipes Antimicrobial Surgical Hand Rub development completed. Submission is now being prepared for registration on the Therapeutic Goods Administration (TGA) register.

Successful working capital initiatives:

- Refreshment to allow further capital-raising secured following today's EGM.
- In final stages of negotiations for more accessible long-term funding from new USA-based institutional investor, to enable faster assembly and sales of the new MetaMizer 240SSS.
- Investigating MDV being quoted on the OTC QX Exchange.

Focus now on sales:

- Sale(s) imminent for new MetaMizer 240SSS.
- Further progress on major export order for MetaMizer 240SSS in Sri Lanka.
- Distribution contract from NSW Ambulance for SunnyWipes.
- Growing interest in new MetaMizer in Australia and from other export markets.

Executive Chairman of MediVac Limited, Mr Paul McPherson, said: "With the majority of our development work completed, now is the time to convert this investment and effort into sales – FY2012 promises to be an exciting year in the evolution of MediVac Limited. Today's EGM result allows us to finalise funding to satisfy this anticipated growth."

P. D. Mehern

Paul McPherson Executive Chairman



About MediVac Limited: "MDV"

MediVac delivers cleaner, safer healthcare solutions.

MediVac Technology offers a best practice solution to the handling and remediation of clinical waste. The MetaMizer is an environmentally friendly alternative waste management system for hospitals and quarantine facilities, providing sterile, safe waste disposal on site and reducing waste to landfill by up to 90%.

SunnyWipes are a range of powerful hard surface wipes and hand sanitising gels produced with ingredients derived from natural sources. Using green chemistry, SunnyWipes provides a more natural solution for infection control and disinfection on topical skin and non-porous hard surfaces. SunnyWipes decrease human and environmental health risks.

Media enquiries:

Richard Allen Oxygen Financial Public Relations Ph: 03 9915 6341



Cleaner, Safer, Healthcare Solutions

Extraordinary General Meeting Market Update 22 July, 2011

MediVac Limited. a: P.O.Box 656 Baulkham Hills NSW 1755 p: +61 2 9630 0633 w: www.medivac.com.au e: paul.mcpherson@medivac.com.au



Our Mission



To build shareholder value by profitably developing & commercialising cleaner, safer healthcare solutions for Domestic and International markets.



Market Update

- Improved Result for FY 2011
 - Expect (unaudited) results for FY 2011 to show a 20% to 25% improvement (reduction in net loss) compared to the 2010 year.
- Key research & development activities completed :
 - First new MetaMizer 240 SSS has now been completed
 - Currently in rigorous testing results to date are exceeding expectations including faster throughout, even higher capacity, and ability to treat alterative feedstock.
 - New Sunnywipes Antimicrobial Surgical Hand Rub development completed and submission being prepared for registration on the Therapeutic Goods (TGA) register
- Successful working capital initiatives:
 - Refreshment to allow further capital raising secured following today's EGM
 - In final stages of negotiation for more accessible long term funding from new USA based institutional investor, to enable faster assembly and sales of the new MetaMizer 240SSS
 - Investigating MDV being quoted on the OTC QX Exchange
- Focus now on sales
 - Sale(s) imminent for new MetaMizer 240SSS
 - > Further progress on major export order for MetaMizer 240SSS in Sri Lanka
 - Distribution contract from NSW Ambulance for SunnyWipes
 - Growing interest in new MetaMizer in Australia and from other export markets



technology Mediate Solutions Cleaner, Safer, Clinical Waste Solutions



New MetaMizer 240 SSS

- Rigorous testing exceeding expectations faster throughput, potentially higher capacity
- Successful with treating other hospital waste (e.g. food) for remote locations
- Second unit already commenced
- Sales pipeline domestic & export growing





SunnyWipes R & D

Cleaner, Safer, Healthcare Solutions

- Natural based surgical hand rub completed
- Successful efficacy, safety and stability results just received yesterday.
 - ABHR (alcohol based hand rub) for surgical use compliant to EN 12791
 - Skin wash pre op antiseptic
 - Sustained effect compliant to EN 1500
- TGA submission being prepared



Appendix - Disclaimer

DISCLAIMER

This Power Point summary ("PP") is not an offer, invitation or recommendation to any recipient or to any other persons to subscribe for securities in the Company and simply sets out information to allow potential investors to consider and evaluate the merits of the various businesses that comprise the Company. To the extent it is included with, or taken to be, an offer of the securities in the Company, it is only an offer, and may only be taken to be an offer, in the circumstances where, pursuant to Section 708 of the Corporations Act 2001, a disclosure document is not required. No steps have been taken for the lawful receipt or distribution of this ES in any jurisdiction outside Australia.

RESPONSIBILITY

The Company is the issuer of this PP. Neither the Company nor its advisers have independently verified any of the information contained in the PP, including any forecast or projected information and any assumptions upon which those statements are based.

None of the Company or its Directors:

• make (and will not make) any representation or warranty (express or implied) regarding; or

• accept (and will not accept) any responsibility or liability (including negligence) for, the truth, accuracy or completeness of any statement, opinion, forecast, information or other matter (whether expressed or implied) in this PP.

None of the Company or its Directors, have (and will not have) any responsibility or liability (including in negligence):

• for, or in connection with, any act or omission directly or indirectly in reliance upon; or

• for any expense, loss or other liability directly or indirectly arising from, or in connection with, any omission from or defects in, or any failure to correct any information in this PP or any other communication (written or oral) about or concerning the Company, and/or the issue of shares in the Company.

This PP includes certain statements with respect to the Company's future operations and performance. Such statements reflect various assumptions made by the Directors of the Company concerning, or which are relevant to, the anticipated operations of the Company. Those assumptions and/or anticipated operations of the Company are and will be subject to uncertainties and contingencies many, if not all, of which are outside the control of the Company. Therefore, those assumptions and/or anticipated returns may or may not prove to be correct or valid. While the statements and estimates made by the Company and contained in this PP genuinely represent the views of the persons to whom they are attributed, they involve subjective judgement and analysis that may or may not be correct. No representations or warranties are (or will be made), and no responsibility or liability (including in negligence) is (or will be) accepted by the Company or the Directors as to the truth, accuracy or completeness of such statements, assumptions or estimations or projections (and no such representations or warranties should be inferred).



Cleaner, Safer, Healthcare Solutions

Extraordinary General Meeting Market Update 4 May, 2011

MediVac Limited. a: P.O.Box 656 Baulkham Hills NSW 1755 p: +61 2 9630 0633 w: www.medivac.com.au e: paul.mcpherson@medivac.com.au